| Literature DB >> 35169171 |
Mauricio Beitia Kraemer1, Denise Gonçalves Priolli1, Ivan Gustavo Masseli Reis1, Andrea Corazzi Pelosi1, Ana Luíza Paula Garbuio1, Leonardo Henrique Dalcheco Messias2.
Abstract
This systematic review and meta-analysis of randomized controlled trials tested the effects of home-based, supervised, or mixed exercise interventions on the functional capacity (FC) and quality of life (QoL) in colorectal cancer patients. A literature search was performed using the PubMed, Embase, Cochrane, and Medline databases. Two reviewers screened the literature through March 10, 2021 for studies related to exercise and colorectal cancer. Of the 1161 screened studies in the initial search, 13 studies met the eligibility criteria (home-based = 6 studies; supervised or mixed = 7 studies). Overall, 706 patients were enrolled in the trials, and 372 patients were submitted to home-based, supervised, or mixed exercise intervention. The overall results from the main meta-analysis showed a significant effect regarding supervised or mixed intervention (6 studies; p = 0.002; I2 = 43%; PI 0.41-1.39); however, no significant effect was observed for home-based intervention (5 studies; p = 0.05; I2 = 25%; PI - 0.34-0.76). A sensitivity analysis based on studies with intervention adherence ≥ 80% (home-based = 3 studies; supervised or mixed = 4 studies) revealed that home-based intervention or intervention entirely supervised or with some level of supervision (mixed) are effective in improving the QoL and FC of CRC patients. In summary, this meta-analysis verified that supervised and home-based exercise can modify QoL and FC when intervention adherence ≥ 80%. Regardless of the supervision characteristics, future RCTs are strongly encouraged to provide a detailed description of the exercise variables in physical interventions for CRC prescription. This perspective will allow a refined exercise prescription for patients with CRC, mainly according to their clinical status.Entities:
Mesh:
Year: 2022 PMID: 35169171 PMCID: PMC8847564 DOI: 10.1038/s41598-022-06165-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Eligibility criteria for inclusion of studies in this systematic review according to the PICOS (population, intervention, comparator, outcomes, and study design) criteria.
| Components | Feature |
|---|---|
| Population | CRC patients |
| Intervention | Home-based, supervised, or mixed physical exercise interventions |
| Comparator | CRC patients not enrolled in physical exercise intervention |
| Outcomes | Quality of life and functional capacity measures |
| Study design | Randomized-controlled trials |
CRC colorectal cancer.
Figure 1Flow diagram of the preferred reporting items for systematic reviews and meta-analyses (PRISMA).
Overview of the included studies.
| Study | Sample size and age | Patients’ status and eligibility criteria | Stage of cancer | Tumor location |
|---|---|---|---|---|
| Courneya et al. (2003)[ | n = 31 (M = 20; F = 11); age = 61 ± 13 year n = 62 (M = 34; F = 28); age = 59 ± 10 year | Patients who had surgery for CRC within the past 3 months and have recovered from it | I–II (n = 4) III (n = 27) I–II (n = 14); III (n = 44); IV (n = 4) | Colon (74.2%) Rectum (25.8%) Colon (77%) Rectum (23%) |
| Ahn et al. (2013)[ | n = 14 (M = 5; F = 9); age = 57 ± 6 year n = 17 (M = 12; F = 5); age = 55 ± 7 year | Patients diagnosed with stages I–III of CRC | I (n = 3); II (n = 6); III (n = 5) I (n = 7); II (n = 5); III (n = 5) | Ascending (43%) Transverse (7%) Descending (7%) Sigmoid (0%) Rectosigmoid (43%) Splenic Flexure (0%) Ascending (24%) Transverse (6%) Descending (0%) Sigmoid (6%) Rectosigmoid (53%) Splenic Flexure (12%) |
| Pinto et al. (2013)[ | n = 26 (M = 12; F = 14); age = 55 ± 8 year n = 20 (M = 8; F = 12); age = 59 ± 11 year | Sedentary patients who completed (≤ 5 year) primary and adjuvant treatments for stages I–III of CRC | Patients who completed primary and adjuvant treatments for colon or rectal cancer (stages I–III) | Colon (58%) Rectum (42%) Colon (55%) Rectum (45%) |
| Lin et al. (2014)[ | n = 24 (M = 15; F = 9); age = 54 ± 10 year n = 21 (M = 11; F = 10); age = 59 ± 9 year | Patients diagnosed with stages II–III of CRC, had undergone elective, abdominal colorectal surgery and had ECOG performance less than 3 | IIA (n = 6); IIB (n = 0); IIIA (n = 4); IIIB (n = 10); IIIC (n = 4) IIA (n = 4); IIB (n = 4); IIIA (n = 2); IIIB (n = 4); IIIC (n = 7) | Not specified |
| Cantarero-Villanueva et al. (2016)[ | n = 19 (M = 13; F = 6); age = 62 ± 7 year n = 21 (M = 13; F = 8); age = 57 ± 5 yr | Patients who received curative treatment due to cancer and completed coadjuvant treatment | II (n = 7); IIIa (n = 12) II (n = 7); IIIa (n = 14) | Not specified |
| Lee et al. (2017)[ | n = 61 (M = 28; F = 33); age = 56 ± 9 years n = 62 (M = 31; F = 31); age = 56 ± 9 years | Patients diagnosed with stages II–III of CRC, completed surgery, radiotherapy, and/or chemotherapy within four weeks to two years before study enrollment, and ECOG performance status of 0 or 1 | II (n = 23); III (n = 38) II (n = 34); III (n = 27) | Colon (65.6%) Rectum (34.4%) Colon (72.1%) Rectum (27.9%) |
| Zimmer et al. (2018)[ | n = 13 (M = 9; F = 4); age = 70 yearsa n = 17 (M = 12; F = 5); age = 68 yearsa | Patients with metastasized CRC and estimated life expectancy of at least 6 months | IV (n = 13) IV (n = 17) | Cecum/Colon (52.9%) Rectosigmoid (11.8%) Rectum (35.3%) Cecum/Colon (61.5%) Rectosigmoid (7.7%) Rectum (30.8%) |
| Lee et al. (2018)[ | n = 34 (M = 17; F = 17); age = 56 ± 10 years n = 38 (M = 18; F = 20); age = 55 ± 8 years | Patients diagnosed with stages II—III of CRC, completed surgery radiotherapy, and/or chemotherapy within four weeks to two years before study enrollment | II (n = 12); III (n = 22) II (n = 21); III (n = 17) | Colon (55.9%) Rectum (44.1%) Colon (71.1%) Rectum (28.9%) |
| Kim et al. (2019)[ | n = 34 (M = 17; F = 17); age = 56 ± 10 years n = 37 (M = 18; F = 19); age = 55 ± 8 years | Patients diagnosed with stages II–III of CRC, completed surgery radiotherapy, and/or chemotherapy within 4 weeks to 2 years before study enrollment and ECOG performance status of 0 or 1 | II (n = 12); III (n = 22) II (n = 21); III (n = 16) | Colon (73%) Rectum (27%) Colon (55.9%) Rectum (44.1% |
| Lu et al. (2019)[ | n = 44 (M = 30; F = 14); age = 54 ± 11 year n = 43 (M = 26; F = 17); age = 55 ± 11 year | Patients undergoing chemotherapy diagnosed with stages I–III of CRC and had surgical resection of gastrointestinal tumors by laparotomy or laparoscopy under general anesthesia | I (n = 13); II (n = 26); III (n = 5) I (n = 10); II (n = 29); III (n = 4) | Colon (36%) Rectum (64%) Colon (42%) Rectum (58%) |
| Christensen et al. (2019)[ | n = 20 (M = 11; F = 9); age = 60 ± 8 years n = 19 (M = 7; F = 12); age = 57 ± 10 year | Patients with CRC who had completed surgery for local stage disease (UICC stage I to IIa) and patients who had completed surgery and any adjuvant chemotherapy for locally advanced-stage disease (UICC stage IIb to III) | I (n = 4); II (n = 7); III (n = 9) I (n = 6); II (n = 4); III (n = 9) | Colon (85%) Rectum (15%) Colon (74%) Rectum (26%) |
| Karlsson et al. (2019)[ | n = 11 (M = 4; F = 7); age = 74 yearsb n = 10 (M = 4; F = 6); age = 83 yearsb | Patients scheduled for surgery due to CRC or suspected CRC | 0 (n = 2); I (n = 3); II (n = 1); III (n = 5) II (n = 5); III (n = 4); IV (n = 1) | Colon (82%) Rectum (18%) Colon (90%) Rectum (10%) |
| Hwang et al. (2020)[ | n = 3 (M = 1; F = 2); age = 62 ± 13 years n = 5 (M = 2; F = 3); age = 54 ± 10 year | Patients diagnosed with stages II–IV of CRC, underwent surgery for the primary treatment completed adjuvant chemotherapy or radiotherapy at least 5 years before study participation and ECOG performance status of 0–2 | I–IV (not specified by stage or group) | Colon (62.5%) Rectum (37.5%) Colon (60%) Rectum (40%) |
Note that only the most important eligibility criteria of studies (according to this systematic review goals) were included; avariation not specified; bmedian.
M male, F female, ECOG Eastern Cooperative Oncology Group, UICC Union for International Cancer Control.
Studies design and Quality of Life (QoL) and Functional Capacity (FC) outcomes of home-based exercise interventions in colorectal patients.
| Study | Length of intervention (L) (weeks) | Exercise session duration (D) | Exercises | Instrument for QoL measurement (parameter) | QoL results | Instrument for FC measurement (parameter) | FC results |
|---|---|---|---|---|---|---|---|
| Courneya et al. (2003)[ | L = 16 F = 3–5 A: 75.8 | D = 20–30 min I = 65–75% of the HRmax | Swimming, cycling or walking | FACT-C (score) | Pre = 107.0 ± 16.0 Pos = 109.8 ± 18.8 Pre = 106.0 ± 14.0 Pos = 107.4 ± 16.5 | Modified Balk Treadmill Test (time spent in the test) | Pre = 314 ± 270 s Pos = 406 ± 301 s Pre = 396 ± 291 s Pos = 548 ± 300 s |
| Pinto et al. (2013)[ | L = 12 F = 2–5 A: 76 | D = 10–30 min I = 64–76% of the HRmax | Brisk walking, biking, or use of home exercise equipment | FACT-C (score) | Pre = 105.3 Pos = 110.8 Pre = 105.3 Pos = 111.3 | Treadwalk test (VO2peak) | Pre = 22.9 ml/kg/min Pos = 23.7 ml/kg/min Pre = 22.9 ml/kg/min Pre = 27.6 ml/kg/mina |
| Lee et al. (2017)[ | L = 12 F = First 6 weeks–> 18 MET-hours A: 86.3 F = After 6th week–27 MET-hours A: 74.5 Mean total adherence: 80.4 | D = > 10,000 steps plus 30 min of resistance exercises using the body weight I = Of the 10.000 steps, 3.000 should be up to 65% of the HRmax | Brisk walking, hiking, stationary bike, and resistance exercises with own body mass | NA | NA | 6-MWT (distance covered) | Pre = 598 ± 75 m Pos = 588 ± 72 m Pre = 578 ± 79 m Pos = 603 ± 74 ma |
| Lee et al. (2018)[ | L = 6 F = > 18 MET-hours A: 73.5 | D = > 10,000 steps plus 30 min of resistance exercises using the body weight I = Of the 10.000 steps, 3.000 should be up to 65% of the HRmax | Brisk walking, hiking, stationary bike, and resistance exercises with own body mass | NA | NA | Tecumseh test (HR measured 1 min after the test) 6-MWT (distance covered) | Tecumseh— Pre = 93 ± 14 bpm Pos = 95 ± 13 bpm Tecumseh— Pre = 92 ± 13 bpm Pos = 88 ± 13 bpma 6-MWT— Pre = 582 ± 70 m Pos = 594 ± 96 m 6-MWT— Pre = 576 ± 85 m Pos = 585 ± 82 m |
| Kim et al. (2019)[ | L = 12 F = First 6 weeks—> 18 MET-hours F = After 6th week—27 MET-hours A: 81.1c | D = > 10,000 steps plus 30 min of resistance exercises using the body weight I = Of the 10.000 steps, 3.000 should be up to 65% of the HRmax | Brisk walking, hiking, stationary bike, and resistance exercises with own body mass | TOI (score) FACT-C (score) | TOI— Pre = 63.4 ± 13.1 Pos = 64.3 ± 12.4 TOI— Pre = 64.1 ± 11.2 Pos = 66.3 ± 11.8a FACT-C— Pre = 97.5 ± 19.9 Pos = 99.1 ± 19.1 FACT-C— Pre = 100.5 ± 18.1 Pos = 104.3 ± 17.5a | NA | NA |
| Christensen et al. (2019)[ | L = 12 F = 150 min/week performed according to the patient’s preferences A: Training logs = 102 ± 16 A: InterWalk = 79 ± 10 Mean total adherence: 90.5b | Not specified | Walking | TOI (score) FACT-C (score) | TOI— Pre = 66.4 ± 12.7 Pos = 68.4 ± 10.2 TOI— Pre = 68.0 ± 11.6 Pos = 73.8 ± 7.6a FACT-C— Pre = 108 ± 19 Pos = 110 ± 18 FACT-C— Pre = 112 ± 17 Pos = 121 ± 11a | Incremental test (VO2peak) | Pre = 26.1 ± 6.0 ml/kg/min Pos = 24.8 ± 5.7 ml/kg/min Pre = 26.9 ± 6.9 ml/kg/min Pos = 26.4 ± 5.7 ml/kg/min |
HRmax maximum heart rate, FACT-C functional assessment of cancer therapy-colorectal, VO2 peak oxygen uptake, 6-MWT 6 Minute Walk Test, TOI-PEC trial outcome index-physical/functional/colorectal.
aDenote difference from Pre.
bThe adherence was obtained by training logs and an application named InterWalk.
cRetention rate.
Figure 2Meta-analysis of quality of life (QoL) and functional capacity (FC) measured in randomized controlled trials that conducted home-based exercise intervention for colorectal cancer patients.
Figure 3Sensitivity analysis of quality of life (QoL) and functional capacity (FC) measured in randomized controlled trials that conducted home-based exercise intervention with ≥ 80% adherence for colorectal cancer patients.
Studies design and Quality of Life (QoL) and Functional Capacity (FC) outcomes of supervised exercise interventions in colorectal patients.
| Study | Length of intervention (P) (weeks) | Exercise session duration (D) | Exercises | Instrument for QoL measurement (parameter) | QoL results | Instrument for FC measurement (parameter) | FC results |
|---|---|---|---|---|---|---|---|
| Lin et al. (2014)[ | L = 12 F = 2 A: 73 | D = 40–60 min I = Initial—40–55% of the HRmax or 11–12 of RPE Progressed—60–75% of the HRmax or 14–15 of RPE | Aerobic—cycling Resistance—theraband, dumbbell, and sandbag | EORTC QLQ-C30 (score) | Pre = 68.1 ± 18.5 Pos = 72.2 ± 17.5 Pre = 67.9 ± 16.3 Pos = 71.4 ± 19.8 | 6-MWT (distance covered) | Pre = 505 ± 117 m Pos = 550 ± 121 m Pre = 491 ± 91 m Pos = 550 ± 85 m Effect of time p = 0.02 |
| Cantarero-Villanueva et al. (2016)[ | L = 8 F = 4 A: 88.3 | D = 90 min I = not specified | Aerobic—Brisk walking or running Stabilization—pilates, including local segmental control exercise, roll up-roll down, one leg circle, side kicks, saw, hundred and leg pull front Stretching | NA | NA | 6-MWT (distance covered) | Pre = 288 ± 132 m Pos = 293 ± 125 m Pre = 330 ± 137 m Pos = 410 ± 130 m Interaction p < 0.01 |
| Zimmer et al. (2018)[ | L = 8 F = 2 A: 80 | D = 60 min I = Endurance training—60–70% of the HRmax or 12–13 of RPE Resistance training—60–80% of 1RM or 6 score at Borg CR10 | Phase 1—Balancing and coordination practices Phase 2—cross-training, cycling, or walking (Endurance) and bench press, lat pulldown, leg press, seated row, and abdominal (Resistance) Phase 3—relaxing, stretching, breathing and mobilization | TOI (score) | Pre = 71.5 ± 13.0 Pos = 64.4 ± 11.5 Pre = 75.0 ± 14.8 Pos = 77.3 ± 11.8 | 6-MWT (distance covered) | Pre = 459 ± 74 m Pos = 478 ± 75 m Pre = 477 ± 91 m Pos = 502 ± 62 m |
| Lu et al. (2019)[ | L = 24 F = 5 A: 95a | D = 20–40 min I = Not specified | Baduanjin qigong | BFI (score) | Pre = 4.7 ± 2.5 Pos 1 = 4.4 ± 2.4 Pos 2 = 4.1 ± 1.9 Pre = 4.4 ± 2.2 Pos 1 = 4.3 ± 2.1 Pos 2 = 2.7 ± 2.1 Effect of time p < 0.01 Interaction p < 0.01 | NA | NA |
The EORTC QLQ-C30 provides several outcomes related to the quality of life. Therefore, we opted to expose those who were modified by the intervention; Pos 1—reevaluation at the 12th week; Pos 2—reevaluation at the 24th.
EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire, 6-MWT 6 Minute Walk Test, TOI Trial Outcome Index, RPE Rating of perceived exertion, HR Maximum Heart Rate, 1RM one maximum repetition, Borg CR10 Borg's category ratio-scale, BFI Brief Fatigue Inventory.
aRetention rate.
Studies design and Quality of Life (QoL) and Functional Capacity (FC) outcomes of exercise interventions with some level of supervision (i.e. mixed) in colorectal patients.
| Study | Length of intervention (P) (weeks) | Exercise session duration (D) | Exercises | Instrument for QOL measurement (parameter) | QOL results | Instrument for FC measurement (parameter) | FC results |
|---|---|---|---|---|---|---|---|
| Ahn et al. (2013)[ | 9.8 ± 2.6 days Interventiona 7.8 ± 1.0 days Phase 1—Twice/day supervised session plus unsupervised sitting or walking Phase 2—same as phase 1 Phase 3—One supervised and one unsupervised exercise session plus sitting or walking A: 84.5 | Details of supervised and unsupervised session duration not specified Phase 2 -1-lb Weight Phase 3 -not specified | Phase 1—Stretching, core, and resistance exercises (in bed) plus unsupervised sitting or walking in the ward Phase 2—Stretching, core, and resistance exercises (limited ambulation) plus unsupervised walking in the hallway Phase 3—phase 2 exercises plus balancing exercises | NA | NA | Tecumseh test (HR measured 1 min after the test) | Pre = 92 ± 14 bpm Pos = 100 ± 12 bpm Pre = 89 ± 12 bpm Pos = 90 ± 11 bpm |
| Karlsson et al. (2019)[ | Unsupervised—150 min/week performed according to the patient’s preferences A: > 80 | Unsupervised—core set of strength exercised and 30 inspiratory repetitions Strength—7–8 at Borg CR10 Aerobic—7–8 at Borg CR10 | Inspiratory exercise Chair stands and step-up (strength) Stair climbing, Nordic walking outdoors, and interval walking indoors and/or outdoors (aerobic) | NA | NA | 6-MWT (distance covered) | Pre = 432 m Pos 1 = 426 m Pos 2 = 278 m Pre = 418 m Pos 1 = 398 m Pos 2 = 330 m |
| Hwang et al. (2020)[ | Unsupervised—6 A: Not reported | Unsupervised—not specified | Push-up, squat, shoulder press, sit-ups, pelvic tilt, shoulder bridge, bird-dog, pelvic abduction, squeezing ball with knees, calf raise, and superman | NA | NA | Tecumseh test (HR measured 1 min after the test) | Pre = 76 ± 8 bpm Pos = 79 ± 11 bpm Pre = 79 ± 13 bpm Pos = 81 ± 9 bpm |
The results of Karlsson et al.[31] were expressed as median.
HR heart rate, Borg CR10 Borg's category ratio-scale, Pos 1 pre-surgery, Pos 2 pos-surgery.
aThe intervention and its length are directly related.
Figure 4Meta-analysis of quality of life (QoL) and functional capacity (FC) measured in randomized controlled trials that conducted exercise intervention entirely supervised or with some level of supervision (mixed) for colorectal cancer patients.
Figure 5Meta-analysis of quality of life (QoL) and functional capacity (FC) measured in randomized controlled trials that conducted exercise intervention entirely supervised or with some level of supervision (mixed) with ≥ 80 of adherence for colorectal cancer patients.